Jeroen Cammeraat


Jeroen Cammeraat is co-founder and Chairman of the Board of Cassini. A serial entrepreneur and senior executive with 25 years of global experience in the medical technology and life sciences market. A former VP of Philips Electronics, where he joined the healthcare division in 1992. At Philips, he took various commercial and general management roles in the company, including Regional Manager Africa, General Manager of the Netherlands’ healthcare division and CEO of a European telemedicine joint venture.

After 12 years with Philips, he launched the European Discus Dental venture, a rapidly growing privately held cosmetic dental company which was acquired by Philips. From 2005 until 2010 Jeroen joined the global radiation therapy company Nucletron as COO where he led the successful management buy-out in 2007. During that period he was responsible for the global commercial operations with offices in over 15 countries and was living with his family in Bethesda, Maryland, USA. Jeroen holds an MSc degree from the University of Groningen and an INSEAD MBA.


Chris Sonnenberg1

Chris Sonnenberg



Chris has an engineering background and started his career as strategy consultant at Arthur D. Little, helping global tech companies developing and implementing their corporate strategies. In 2010 he joined Parcom Capital, a leading mid-market Private Equity investor where he actively built the offshore energy & maritime and agri technology investment clusters.

Chris led numerous deals & exits and holds several investor/supervisory board positions. He is experienced in a.o. deal structuring & negotiating, due diligence, financing, corporate carve-outs, portfolio management, and exits.


Tom Schwarz1

Tom Schwarz



After obtaining a degree in Pharmacy from the Utrecht University, Tom co-founded U-Gene Research, a contract research organization located at the Utrecht Medical Centre (NL). As the company’s CEO, Tom grew the company in 10 years’ time from a university spin-off into one of Europe’s leading Clinical Pharmacology Units with more than 175 FTEs on the payroll. Tom successfully sold the company in 1997 to Kendle (US), which combination was listed at the Nasdaq in 2007.

After his departure, Tom co-founded Life Sciences Partners (LSP) in 1998, which became a leading European life sciences venture capital fund with offices in Amsterdam, Munich, and Boston.